Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending December 2015. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMRs) in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider share transactions rather than a financial performance report.
Material Changes
The filing details the acquisition of GSK Ordinary Shares by 10 Directors and PDMRs on December 9, 2015. The transactions occurred through GSK's ShareReward Plan at a price of 1324.98 pence per share. No material changes to the company's financial position or operations are reported in this text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The content is limited to the disclosure of specific share purchases.
Important Facts for Investors
- Transaction Date: Shares were acquired on December 9, 2015.
- Share Price: 1324.98 pence per Ordinary Share.
- Participants: 10 Directors/PDMRs participated, including Sir Andrew Witty and Dr P J T Vallance.
- Volume: Most participants acquired 9 shares under the personal contribution element and 9 shares under the matching element; Dr P J T Vallance acquired 10 shares under each element.
- Plan Type: Transactions were executed via the GSK ShareReward Plan.